Vocan is a genetic engineering and biosynthesis firm currently focused on producing pharmaceutical grade psilocybin. The company are producing biologically derived psilocybin, a more cost-effective method compared to chemically derived psilocybin.
Vocan
Vocan’s technology will produce cGMP API grade psilocybin which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials.
In December 2020, Vocan was acquired by Core One Labs for an undisclosed amount.
“Vocan’s mission is to use science and technology to advance the knowledge of natural-based medicines for the treatment of mental health illnesses, including addictions.”
Activities
B2B
B2C
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates